• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用光动力疗法联合米索硝唑治疗邓宁R3327-AT大鼠前列腺肿瘤。

Treatment of Dunning R3327-AT rat prostate tumors with photodynamic therapy in combination with misonidazole.

作者信息

Gonzalez S, Arnfield M R, Meeker B E, Tulip J, Lakey W H, Chapman J D, McPhee M S

出版信息

Cancer Res. 1986 Jun;46(6):2858-62.

PMID:3698010
Abstract

Fischer X Copenhagen rats bearing Dunning R3327-AT tumors were treated with hematoporphyrin derivative and red light (630 nm from an argon-driven dye laser) alone or in combination with the hypoxic cell radiosensitizer, misonidazole (MISO). In vitro studies had suggested that hypoxia might significantly decrease the cytotoxicity of photodynamic therapy (PDT) and labeling with [14C]MISO had revealed a significant fraction of viable hypoxic cells in this tumor. PDT alone resulted in a growth delay of 8.8 days but no tumor cures were observed. The administration of MISO (i.p. at 0.5 mg/g) 33 min prior to PDT resulted in an average growth delay of 15.2 days and tumor cures (local control at 33 days) in 20% of animals treated. If MISO at a similar dosage was administered 30 min after PDT an average growth delay of 16.3 days was measured and tumor cure was observed in 70% of the animals treated. These results suggest that the hypoxic cell fraction in R3327-AT tumors might be a limitation to their curability by PDT. The addition of MISO and/or other hypoxic cell cytotoxic agents to PDT procedures may provide an effective means of treating PDT-resistant hypoxic cells in solid tumors.

摘要

携带Dunning R3327 - AT肿瘤的Fischer X哥本哈根大鼠,单独接受血卟啉衍生物和红光(来自氩离子驱动染料激光的630nm)治疗,或与乏氧细胞放射增敏剂米索硝唑(MISO)联合治疗。体外研究表明,缺氧可能显著降低光动力疗法(PDT)的细胞毒性,用[14C]MISO标记显示该肿瘤中有相当一部分存活的乏氧细胞。单独的PDT导致生长延迟8.8天,但未观察到肿瘤治愈。在PDT前33分钟腹腔注射MISO(0.5mg/g),导致平均生长延迟15.2天,在20%接受治疗的动物中出现肿瘤治愈(33天时局部控制)。如果在PDT后30分钟给予相似剂量的MISO,测得平均生长延迟16.3天,在70%接受治疗的动物中观察到肿瘤治愈。这些结果表明,R3327 - AT肿瘤中的乏氧细胞部分可能是PDT治愈肿瘤的一个限制因素。在PDT过程中添加MISO和/或其他乏氧细胞细胞毒性药物,可能为治疗实体瘤中对PDT耐药的乏氧细胞提供一种有效方法。

相似文献

1
Treatment of Dunning R3327-AT rat prostate tumors with photodynamic therapy in combination with misonidazole.用光动力疗法联合米索硝唑治疗邓宁R3327-AT大鼠前列腺肿瘤。
Cancer Res. 1986 Jun;46(6):2858-62.
2
Fractionated versus standard continuous light delivery in interstitial photodynamic therapy of dunning prostate carcinomas.分次照射与标准连续照射在邓恩前列腺癌间质光动力治疗中的比较
Clin Cancer Res. 2007 Dec 15;13(24):7496-505. doi: 10.1158/1078-0432.CCR-07-1561.
3
The effect of photodynamic therapy on a retinoblastoma-like tumour. An experimental in vitro and in vivo study on the potential use of photodynamic therapy in the treatment of retinoblastoma.光动力疗法对视网膜母细胞瘤样肿瘤的影响。一项关于光动力疗法在视网膜母细胞瘤治疗中潜在应用的体外和体内实验研究。
Acta Ophthalmol Suppl (1985). 1990(197):1-37.
4
Schedule-dependent interaction between Doxorubicin and mTHPC-mediated photodynamic therapy in murine hepatoma in vitro and in vivo.阿霉素与mTHPC介导的光动力疗法在体外和体内小鼠肝癌中的时间依赖性相互作用
Cancer Chemother Pharmacol. 2006 Jan;57(1):65-72. doi: 10.1007/s00280-005-0006-7. Epub 2005 Nov 5.
5
In vivo interaction between radiation and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in the absence or presence of misonidazole in mice.在小鼠体内,研究辐射与1-(2-氯乙基)-3-环己基-1-亚硝基脲在不存在或存在米索硝唑的情况下的相互作用。
Cancer Res. 1985 Jan;45(1):198-202.
6
Nuclear magnetic resonance spectroscopy and sensitizer-adduct measurements of photodynamic therapy-induced ischemia in solid tumors.核磁共振光谱法及光动力疗法诱导实体瘤缺血中敏化剂加合物的测量
J Natl Cancer Inst. 1991 Nov 20;83(22):1650-9. doi: 10.1093/jnci/83.22.1650.
7
Beneficial effects of androgen-primed chemotherapy in the Dunning R3327 G model of prostatic cancer.
Cancer Res. 1991 Apr 1;51(7):1760-5.
8
Long-term regression of the murine mammary adenocarcinoma, LM3, by repeated photodynamic treatments using meso-tetra (4-N-methylpyridinium) porphine.使用中-四(4-N-甲基吡啶鎓)卟啉通过重复光动力治疗对小鼠乳腺腺癌LM3进行长期消退。
Int J Oncol. 2005 Oct;27(4):1053-9.
9
Interaction of photodynamic therapy and hyperthermia: tumor response and cell survival studies after treatment of mice in vivo.光动力疗法与热疗的相互作用:对小鼠进行体内治疗后的肿瘤反应及细胞存活研究
Cancer Res. 1985 Dec;45(12 Pt 1):6071-7.
10
Efficiency of 5-ALA mediated photodynamic therapy on hypoxic prostate cancer: a preclinical study on the Dunning R3327-AT2 rat tumor model.5-ALA 介导的光动力疗法对缺氧前列腺癌的疗效:Dunning R3327-AT2 大鼠肿瘤模型的临床前研究。
Photodiagnosis Photodyn Ther. 2013 Sep;10(3):296-303. doi: 10.1016/j.pdpdt.2013.01.003. Epub 2013 Feb 14.

引用本文的文献

1
Synergetic anticancer effect of combined gemcitabine and photodynamic therapy on pancreatic cancer in vivo.吉西他滨与光动力疗法联合应用对胰腺癌的体内协同抗癌作用。
World J Gastroenterol. 2009 Feb 14;15(6):737-41. doi: 10.3748/wjg.15.737.
2
Photodynamic therapy: a new approach to prostate cancer.光动力疗法:前列腺癌的一种新疗法。
Curr Urol Rep. 2003 Jun;4(3):221-8. doi: 10.1007/s11934-003-0073-4.
3
Enhancement of photodynamic therapy by mitomycin C: a preclinical and clinical study.丝裂霉素C增强光动力疗法:一项临床前和临床研究。
Br J Cancer. 1996 Apr;73(8):945-51. doi: 10.1038/bjc.1996.186.
4
Vascular perfusion and hypoxic areas in RIF-1 tumours after photodynamic therapy.光动力治疗后RIF-1肿瘤中的血管灌注和缺氧区域
Br J Cancer. 1996 Feb;73(3):288-93. doi: 10.1038/bjc.1996.51.
5
Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference to in vivo methods of evaluation.评估硝基咪唑RSU1069及其前药RB6145的生物还原有效性:特别参考体内评估方法。
Cancer Metastasis Rev. 1993 Jun;12(2):177-93. doi: 10.1007/BF00689809.
6
Anti-tumour activity of photodynamic therapy in combination with mitomycin C in nude mice with human colon adenocarcinoma.光动力疗法联合丝裂霉素C对人结肠癌裸鼠的抗肿瘤活性
Br J Cancer. 1995 May;71(5):950-6. doi: 10.1038/bjc.1995.184.
7
Mechanisms for optimising photodynamic therapy: second-generation photosensitisers in combination with mitomycin C.优化光动力疗法的机制:第二代光敏剂与丝裂霉素C联合使用
Br J Cancer. 1995 Aug;72(2):344-50. doi: 10.1038/bjc.1995.336.
8
Current status of photodynamic therapy in oncology.光动力疗法在肿瘤学中的现状
Drugs. 1994 Oct;48(4):510-27. doi: 10.2165/00003495-199448040-00003.
9
Increased efficacy of photodynamic therapy of R3230AC mammary adenocarcinoma by intratumoral injection of Photofrin II.通过瘤内注射光敏剂II提高R3230AC乳腺腺癌光动力疗法的疗效。
Br J Cancer. 1990 Apr;61(4):553-7. doi: 10.1038/bjc.1990.124.
10
Non-invasive monitoring of photodynamic therapy with 99technetium HMPAO scintigraphy.用锝-99m六甲基丙二胺肟闪烁扫描术对光动力疗法进行无创监测。
Br J Cancer. 1992 Apr;65(4):491-7. doi: 10.1038/bjc.1992.102.